| TACE | Transarterial Chemoembolization |
| TARE | Transarterial Radioembolization |
| OS | Overall Survival |
| LC | Local Control |
| SPIDER | Sample, Phenomena of Interest, Design, Evaluation, Research type |
| BCLM | Breast Cancer Liver Metastases |
| MeSH | Medical Subject Headings |
| GDT | GRADEpro Guideline Development Tool |
| PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| SMA | Superior Mesenteric Artery |
| DEBs | Drug-Eluting Beads |
| Y90 | Yttrium-90 |
| 99mTc | Technetium-99m |
| MAA | Macroaggregated Albumin |
| PVA | Polyvinyl Alcohol |
| CHT | Chemotherapy |
| ORR | Overall Response Rate |
| SD | Stable Disease |
| PD | Progressive Disease |
| DSM | Degradable Starch Microspheres |
| Unk | Unknown |
| CT | Computed Tomography |
| MRI | Magnetic Resonance Imaging |
| PET | Positron Emission Tomography |
| ODC | Overall Disease Control |
| OR | Objective Response |
| ER | Estrogen Receptor |
| ALT | Alanine Aminotransferase |
| AST | Aspartate Aminotransferase |
| GGT | Gamma-Glutamyl Transferase |
| ECOG-PS | Eastern Cooperative Oncology Group Performance Status |
| CTCAE | Common Terminology Criteria for Adverse Events |